Literature DB >> 12579163

The British Ophthalmological Surveillance Unit: an evaluation of the first 3 years.

B Foot1, M Stanford, J Rahi, J Thompson.   

Abstract

We report an evaluation of the British Ophthalmological Surveillance Unit (BOSU), a nationwide active surveillance scheme to assist with the case ascertainment of rare eye conditions. The evaluation assessed participation rates, study applications and research outputs. In addition, through an anonymous postal survey we ascertained the opinions of ophthalmologists regarding the usefulness, levels of feedback, barriers to participation and levels of case ascertainment. Over the first 3 years, the 4-month mean participation rate has improved from 58% to 71%. Ten studies have used this system for case ascertainment. To date three journal publications and 10 conference presentations have reported findings from these studies. It was observed that 582/870 (68%) questionnaires were returned by ophthalmologists, of whom 95% considered BOSU as very or quite useful. In all, 71% reported overall feedback to be sufficient. However, 34% requested greater feedback from research groups. Reported barriers to effective participation were 'having to remember the patient's identity' (52%) and paying for return postage of cards (22%). However, 72% of respondents did not consider the work involved in reporting a case to be prohibitive. Self-reported levels of case ascertainment by ophthalmologists for completed studies ranged between 72% and 95%. This population-based surveillance system provides an effective method for prospective case identification and subsequent data collection. It enables the study of sufficiently representative samples to allow meaningful epidemiological analysis and avoid bias. Its success relies upon the high level of support that it currently receives from ophthalmologists.

Entities:  

Mesh:

Year:  2003        PMID: 12579163     DOI: 10.1038/sj.eye.6700233

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  24 in total

1.  Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study.

Authors:  T F Cochrane; G Silvestri; C McDowell; B Foot; C E McAvoy
Journal:  Eye (Lond)       Date:  2012-01-27       Impact factor: 3.775

2.  Severe intraocular pressure rise following intravitreal triamcinolone: a national survey to estimate incidence and describe case profiles.

Authors:  S Jain; J R Thompson; B Foot; A Tatham; T Eke
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

3.  Trends in serious ocular trauma in Scotland.

Authors:  P Desai; D S Morris; D C Minassian; C J MacEwen
Journal:  Eye (Lond)       Date:  2015-02-13       Impact factor: 3.775

4.  Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome.

Authors:  B Foot; C MacEwen
Journal:  Eye (Lond)       Date:  2017-01-27       Impact factor: 3.775

5.  Surveillance of late-onset bleb leak, blebitis and bleb-related endophthalmitis--a UK incidence study.

Authors:  A Alwitry; A J King
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-17       Impact factor: 3.117

6.  [Status and perspectives of registry-based studies in German ophthalmology].

Authors:  M Roth; C Holtmann; D Böhringer; R P Finger; N Eter; B Seitz; G Geerling
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

7.  Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand.

Authors:  Samantha Bobba; Connor Devlin; Nick Di Girolamo; Denis Wakefield; Peter McCluskey; Elsie Chan; Mark Daniell; Stephanie Watson
Journal:  Eye (Lond)       Date:  2018-06-19       Impact factor: 3.775

8.  The incidence of serious eye injury in Scotland: a prospective study.

Authors:  D S Morris; S Willis; D Minassian; B Foot; P Desai; C J MacEwen
Journal:  Eye (Lond)       Date:  2013-10-04       Impact factor: 3.775

9.  Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.

Authors:  D A M Lyall; A Tey; B Foot; S T D Roxburgh; M Virdi; C Robertson; C J MacEwen
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

10.  Symptomatic toxoplasma infection due to congenital and postnatally acquired infection.

Authors:  R Gilbert; H K Tan; S Cliffe; E Guy; M Stanford
Journal:  Arch Dis Child       Date:  2006-03-17       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.